Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
01 7Myslee
02 4Myslee/Ambien/Stilnox
03 1Stilnox
04 1Stilnox/Ambien/Myslee
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 239
2018 Revenue in Millions : 252
Growth (%) : -5
Main Therapeutic Indication : Sleep Disorders
Currency : USD
2014 Revenue in Millions : -21.70%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Sleep Disorders
Currency : USD
2015 Revenue in Millions : 337
2014 Revenue in Millions : 337
Growth (%) : 0%
Main Therapeutic Indication : Sleep Disorders
Currency : USD
2016 Revenue in Millions : 322
2015 Revenue in Millions : 324
Growth (%) : -1
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 321
2016 Revenue in Millions : 377
Growth (%) : -15
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 261
2017 Revenue in Millions : 293
Growth (%) : -11%
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 73
2019 Revenue in Millions : 86
Growth (%) : -15
Main Therapeutic Indication : Sleep
Currency : USD
2021 Revenue in Millions : 60
2020 Revenue in Millions : 73
Growth (%) : -11
Main Therapeutic Indication : Sleep
Currency : USD
2022 Revenue in Millions : 46
2021 Revenue in Millions : 59
Growth (%) : -21
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 102
2017 Revenue in Millions : 122
Growth (%) : -17%
LOOKING FOR A SUPPLIER?